Investors sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading hours on Monday. $113.33 million flowed into the stock on the tick-up and $231.62 million flowed out of the stock on the tick-down, for a money net flow of $118.29 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 6th highest net out-flow for the day. Johnson & Johnson traded up $0.47 for the day and closed at $139.96

Several research firms have recently weighed in on JNJ. Wells Fargo & Co restated an “outperform” rating and set a $160.00 price objective on shares of Johnson & Johnson in a research report on Friday. Credit Suisse Group set a $151.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, June 12th. Jefferies Financial Group set a $145.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Sunday, July 15th. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Finally, Sanford C. Bernstein began coverage on shares of Johnson & Johnson in a research report on Wednesday, June 27th. They set a “market perform” rating and a $129.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $142.87.

The firm has a market capitalization of $373.89 billion, a P/E ratio of 19.17, a PEG ratio of 2.13 and a beta of 0.69. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 17th. The company reported $2.10 EPS for the quarter, topping the consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The company had revenue of $20.83 billion during the quarter, compared to analysts’ expectations of $20.39 billion. During the same period last year, the company posted $1.83 earnings per share. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. equities research analysts expect that Johnson & Johnson will post 8.14 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 11th. Shareholders of record on Tuesday, August 28th were issued a $0.90 dividend. This represents a $3.60 annualized dividend and a dividend yield of 2.57%. The ex-dividend date was Monday, August 27th. Johnson & Johnson’s payout ratio is 49.32%.

In other news, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the sale, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the sale, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The disclosure for this sale can be found here. Company insiders own 0.22% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its holdings in Johnson & Johnson by 1.7% during the second quarter. BlackRock Inc. now owns 178,310,265 shares of the company’s stock valued at $21,636,166,000 after purchasing an additional 2,921,241 shares during the last quarter. Phocas Financial Corp. grew its holdings in Johnson & Johnson by 999,927.7% during the second quarter. Phocas Financial Corp. now owns 129,463,583 shares of the company’s stock valued at $1,571,000 after purchasing an additional 129,450,637 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Johnson & Johnson by 0.6% during the second quarter. Bank of New York Mellon Corp now owns 33,456,996 shares of the company’s stock valued at $4,059,673,000 after purchasing an additional 185,136 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Johnson & Johnson by 1.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 30,303,272 shares of the company’s stock valued at $3,676,999,000 after purchasing an additional 541,338 shares during the last quarter. Finally, Glenmede Trust Co. NA grew its holdings in Johnson & Johnson by 149.8% during the second quarter. Glenmede Trust Co. NA now owns 22,174,682 shares of the company’s stock valued at $2,690,676,000 after purchasing an additional 13,295,992 shares during the last quarter. 66.80% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile (NYSE:JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Understanding Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.